Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946316 | 0.90 | CHRM4 (0.69) | CHRM4CHRM2CHRM1CHRM3CHRM5 | |
| SCHEMBL3942812 | 0.89 | CHRM4 (0.55) | CHRM4 | |
| SCHEMBL3599853 | 0.86 | CHRM2 (0.60) | CHRM4CHRM2CHRM1CHRM3CHRM5 | |
| SCHEMBL3599975 | 0.83 | CCR8 (0.58) | CHRM4 | |
| SCHEMBL29432389 | 0.81 | CHRM4 (1.00) | CHRM4CHRM2CHRM1 | |
| SCHEMBL3598498 | 0.81 | CCR8 (0.53) | — | |
| SCHEMBL4848254 | 0.81 | CCR2 (0.74) | CHRM4KCNH2CACNA1I | |
| SCHEMBL5709492 | 0.80 | CHRM4 (0.61) | CHRM4CHRM2CHRM1KCNH2CHRM3 | |
| SCHEMBL3940943 | 0.80 | CHRM4 (0.57) | CHRM4CHRM2CHRM1 | |
| SCHEMBL17099436 | 0.79 | NOTUM (0.64) | CHRM4CHRM2CHRM1CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CHRM4 2647/4885CHRM2 3417/4885CHRM1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.